Kurkowski Sarah C, Thimmesch Michael J, Abdelghani Amro, Abdelgadir Yasir H
Medical School, Medical College of Wisconsin, Milwaukee, USA.
Internal Medicine, Medical College of Wisconsin, Milwaukee, USA.
Cureus. 2022 Jun 23;14(6):e26246. doi: 10.7759/cureus.26246. eCollection 2022 Jun.
We present a novel case of de novo membranous nephropathy (DNMN) leading to transplant rejection in a 51-year-old female patient. The patient has a transplant history of two renal transplants for end-stage renal disease due to lupus nephritis. She had a prior unrelated, living donor kidney transplant that was subsequently replaced by a deceased donor kidney transplant due to graft failure. This patient's case is intriguing because DNMN is a rare cause of transplant rejection, and the literature demonstrates a scarcity of clinical examples. Interestingly, post-transplant DNMN has been suggested to be a separate disease from recurrent post-transplant MN and is associated with separate risk factors and diagnostic findings. As DNMN is considered a manifestation of antibody-mediated rejection, it should be treated with immunosuppressive therapy. As such, the presented case has received immunosuppressive therapy. In addition, DNMN is associated with humoral alloimmunity. Potentially other inflammatory processes (such as infection/potential UTI in our patient's case) could cause exposure to undetectable donor antigens on renal transplants leading to antibody-mediated rejection via DNMN.
我们报告了一例51岁女性患者发生的新型原发性膜性肾病(DNMN)导致移植肾排斥反应的病例。该患者有因狼疮性肾炎导致终末期肾病而接受两次肾移植的病史。她曾接受过一次非亲属活体供肾移植,随后因移植肾失功而接受了一次尸体供肾移植。该患者的病例很有趣,因为DNMN是移植肾排斥反应的罕见原因,且文献显示临床病例稀少。有趣的是,移植后DNMN被认为是一种与复发性移植后膜性肾病不同的疾病,并且与不同的危险因素和诊断结果相关。由于DNMN被认为是抗体介导的排斥反应的一种表现,应采用免疫抑制疗法进行治疗。因此,本病例接受了免疫抑制治疗。此外,DNMN与体液同种免疫相关。潜在的其他炎症过程(如我们患者病例中的感染/潜在尿路感染)可能导致接触肾移植中无法检测到的供体抗原,从而通过DNMN导致抗体介导的排斥反应。